RxDoctor Payments Data

Michael Shen

Critical Care Medicine · Houston, TXNPI 1558471441

Payments from drug & device makers

$564in general payments, 2019–2025

Across 31 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$115
  • AstraZeneca$84
  • Pacira Pharmaceuticals Incorporated$61
  • Mylan Specialty L.p.$49
  • Philips North America LLC$46
  • Sanofi$41
  • plus $170 from 6 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$564 in reported general payments places this provider in the 45th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$28,878
Medicare patients
152
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$145,681
Spiriva RespimatTiotropium Bromide51$51,023
Stiolto RespimatTiotropium Br/Olodaterol Hcl53$37,374
Breo ElliptaFluticasone/Vilanterol36$26,039
Spiriva HandihalerTiotropium Bromide19$22,090
Advair HfaFluticasone Propion/Salmeterol38$22,056
SymbicortBudesonide/Formoterol Fumarate56$18,949
Combivent RespimatIpratropium/Albuterol Sulfate14$14,688
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$12,448
DuleraMometasone/Formoterol15$10,434
Albuterol Sulfate HfaAlbuterol Sulfate152$5,900
Arnuity ElliptaFluticasone Furoate15$5,371
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,300
Ventolin HfaAlbuterol Sulfate44$5,238
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$5,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$115$189,539197 claims
AstraZenecaSymbicort$84$18,94956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →